DCGI Approves Intranasal Covid Booster Dosage Trails

Public on: 29-Jan-2022 Views 1220

DCGI Approves Intranasal Covid Booster Dosage Trails

The Drugs Controller General of India (DCGI) granted Bharat Biotech, the developer of Covaxin, permission to conduct trials of its intranasal booster doses against Covid-19 on Friday (BBV154).

The trials will take place at nine different locations across India, according to news agency ANI.

The DCGI letter stated, "The Phase-3 clinical trial should be done as per protocol multi-centre study to compare immunogenicity and safety of BBV154 with Covaxin."

It would be easier to deliver an intranasal vaccine as a booster dose in mass immunisation efforts, and it would have the ability to prevent transmission.

Last month, Bharat Biotech applied to the FDA for permission to undertake phase 3 trials on the nasal vaccination. The decision comes shortly after Covaxin and Covishield, both from the Serum Institute of India, were given market clearance.

Latest Videos